Cargando…
Reconciling ACEA and MCDA: is there a way forward for measuring cost-effectiveness in the U.S. healthcare setting?
BACKGROUND: The ISPOR Special Task Force (STF) on US Value Assessment Frameworks was agnostic about exactly how to implement the quality-adjusted life year (QALY) as a key element in an overall cost-effectiveness evaluation. But the STF recommended using the cost-per-QALY gained as a starting point...
Autores principales: | Zamora, Bernarda, Garrison, Louis P., Unuigbe, Aig, Towse, Adrian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7923485/ https://www.ncbi.nlm.nih.gov/pubmed/33648523 http://dx.doi.org/10.1186/s12962-021-00266-8 |
Ejemplares similares
-
Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support
por: Garrison, Louis P., et al.
Publicado: (2020) -
The cost-per-QALY threshold in England: Identifying structural uncertainty in the estimates
por: Zamora, Bernarda, et al.
Publicado: (2023) -
Beneficiary Switching Between Traditional Medicare and Medicare Advantage Between 2016 and 2020
por: Unuigbe, Aig, et al.
Publicado: (2022) -
Understanding differences between what alternate propensity score methods estimate
por: Basu, Anirban, et al.
Publicado: (2023) -
Value-Based Pricing and Reimbursement in Personalised Healthcare: Introduction to the Basic Health Economics
por: Garrison, Louis P., et al.
Publicado: (2017)